For the roughly 40% of primary biliary cholangitis patients who fail ursodeoxycholic acid — the standard first-line therapy for decades — the therapeutic landscape has long been bleak, with progressive bile duct destruction, fibrosis, and debilitating symptoms like fatigue and pruritus remaining largely unaddressed. The recent regulatory approval of two peroxisome proliferator-activated receptor (PPAR) agonists is beginning to change that calculus, and understanding why they work at the molecular level is now critical to using them wisely.
This review in Trends in Molecular Medicine synthesizes emerging mechanistic evidence for elafibranor (a dual PPARα/δ agonist) and seladelpar (a selective PPARδ agonist) in PBC. Both compounds appear to operate across at least three distinct biological axes: modulation of cellular immune responses implicated in autoimmune bile duct injury, reduction of bile acid synthesis and attenuation of bile acid cytotoxicity within hepatocytes, and suppression of hepatic stellate cell activation that drives fibrotic remodeling. The review also flags unresolved challenges — including optimal patient stratification, long-term safety data, and the mechanistic overlap between the two agents' receptor selectivity profiles.
PPARs have long been studied in metabolic disease, particularly PPARγ in insulin sensitivity and PPARα in lipid catabolism, but their immunomodulatory and antifibrotic roles in cholestatic liver disease represent a meaningful extension of that pharmacology. The dual-axis benefit — targeting both immune pathology and downstream fibrosis — is what makes this drug class conceptually distinct from purely bile-acid-based interventions like obeticholic acid. That said, this is a mechanistic review, not a head-to-head trial, so direct comparative efficacy between elafibranor and seladelpar remains uncertain. PBC also predominantly affects middle-aged women, a population historically underrepresented in liver disease research, adding an equity dimension to translational progress. Incrementally confirmatory rather than paradigm-shifting, this synthesis nonetheless offers a valuable mechanistic framework for clinicians navigating a newly crowded second-line PBC landscape.